arrow
T

Takashi Ogura

kanagawa cardiovascular & respiratory center
H指数:35
被引数:4,965

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The providing multidisciplinary ILD diagnoses (PROMISE) study – study design of the national registry of Japan facilitating interactive online multidisciplinary discussion diagnosis

提供多学科ILD诊断(PROMISE)研究——日本国家注册研究的设计,促进互动式在线多学科讨论诊断

2026-04-060
OAAI
Upfront combination therapy with nintedanib and antiinflammatory agents for progressive pulmonary fibrosis: a multicentre, single-arm phase 2 study (TOP-ILD)
2026-02-163
PRE
Incidence of diffuse parenchymal lung disease in patients meeting the Berlin definition of acute respiratory distress syndrome on mechanical ventilation

Norisue Y,Yamamoto R,Yamakawa H,Hibino M,Nagai T,Fujimoto Y,等。接受机械通气的患者中,符合柏林定义的急性呼吸窘迫综合征患者弥漫性肺实质疾病的发病率。ERJ Open Res. (2025) 11:01296–2024. doi: 10.1183/23120541.01296-2024。

2025-09-150
OA
Influence of Educational Films on Antiviral Prescription for COVID-19: Insights from Web-Based Survey in Japan
2025-03-070
OA
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis

尼达尼布联合化疗治疗小细胞肺癌合并特发性肺纤维化

2024-04-014
PRE
Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients With Coronavirus Disease 2019 (COVID-19) Using Nationwide Real-World Data: An Observational Matched Cohort Study From the Japan COVID-19 Task Force
2023-06-083
OAAI
Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity

单细胞分析和宿主遗传学强调先天免疫细胞在新型冠状病毒肺炎严重程度中的作用

2023-04-2418
OAAI
The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force
2022-08-2213
OAAI
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
2021-12-3043
OAAI